In a research report released yesterday, Leerink Swann analyst Seamus Fernandez reiterated an Outperform rating on shares of Bristol-Myers Squibb Co (NYSE:BMY), after the …
Bristol-Myers Squibb Co (NYSE:BMY) announced new data across eight tumor types evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), as monotherapy or in combination, as well …
Bristol-Myers Squibb Co (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) announced a new clinical collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) with Nektar’s investigational medicine, NKTR-214, …
Bristol-Myers Squibb Co (NYSE:BMY) announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the current …
Bristol-Myers Squibb Co (NYSE:BMY) announced that the European Commission has approved ORENCIA ® (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, in combination …
Friday morning before market open, Bristol-Myers Squibb Co (NYSE:BMY) came to terms with the failure of its Phase III CheckMate-026 trial evaluating Opdivo …
Bristol-Myers Squibb Co (NYSE:BMY) announced that CheckMate -026, a trial investigating the use of Opdivo(nivolumab) as monotherapy, did not meet its primary endpoint of …
On Monday, Uniqure NV (NASDAQ:QURE) and Bristol-Myers Squibb Co (NYSE:BMY) announced an exclusive strategic collaboration in which the agreement gives Bristol-Myers “exclusive …
This week was a busy one for biopharma BD teams. Finallized on Sunday, Valeant (VRX) will pay $158 per share for Salix Pharmaceuticals (SLXP) in an all-cash …
Durables Miss In Big Way The slow growth/low inflation story gained additional traction Tuesday when durable goods orders came in well below expectations. …
